Study on the effect of a triple cancer treatment of propolis, thermal cycling-hyperthermia, and low-intensity ultrasound on PANC-1 cells.

Publisher: Impact Journals, LLC Country of Publication: United States NLM ID: 101508617 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1945-4589 (Electronic) Linking ISSN: 19454589 NLM ISO Abbreviation: Aging (Albany NY) Subsets: MEDLINE

Original Publication: Albany, NY : Impact Journals, LLC

Propolis*/pharmacology ; Hyperthermia, Induced*/methods ; Pancreatic Neoplasms*/drug therapy ; Pancreatic Neoplasms*/metabolism ; Neoplasms, Multiple Primary*; Humans ; Apoptosis ; Cell Line, Tumor ; Reactive Oxygen Species/metabolism

To reduce side effects and enhance treatment efficacy, study on combination therapy for pancreatic cancer, a deadly cancer, has gained much attraction in recent years. In this study, we propose a novel triple treatment combining propolis and two physical stimuli-thermal cycling-hyperthermia (TC-HT) and low-intensity ultrasound (US). The study found that, after the triple treatment, the cell viability of a human cancer cell line PANC-1 decreased to a level 80% less than the control, without affecting the normal pancreatic cells. Another result was excessive accumulation of reactive oxygen species (ROS) after the triple treatment, leading to the amplification of apoptotic pathway through the MAPK family and mitochondrial dysfunction. This study, to the best of our knowledge, is the first attempt to combine TC-HT, US, and a natural compound in cancer treatment. The combination of TC-HT and US also promotes the anticancer effect of the heat-sensitive chemotherapy drug cisplatin on PANC-1 cells. It is expected that optimized parameters for different agents and different types of cancer will expand the methodology on oncological therapy in a safe manner.

J Bone Joint Surg Br. 1992 Jul;74(4):488-94. (PMID: 1624502)
Pancreatology. 2008;8(6):566-76. (PMID: 18824880)
Cancers (Basel). 2011 Mar 15;3(1):1351-71. (PMID: 24212665)
Diagn Interv Radiol. 2019 Sep;25(5):398-409. (PMID: 31287428)
Hepatology. 2009 May;49(5 Suppl):S122-8. (PMID: 19399796)
BMC Cell Biol. 2013 Jul 09;14:32. (PMID: 23834359)
Int J Oncol. 2019 Sep;55(3):617-628. (PMID: 31322205)
Am J Surg. 1998 Aug;176(2):183-7. (PMID: 9737629)
Exp Ther Med. 2011 Sep;2(5):849-852. (PMID: 22977587)
J Biopharm Stat. 2007;17(3):461-80. (PMID: 17479394)
Ultrasound Med Biol. 2015 Apr;41(4):905-28. (PMID: 25728459)
Cell Death Dis. 2012 Dec 20;3:e449. (PMID: 23254292)
Cancer Sci. 2008 May;99(5):1055-62. (PMID: 18380794)
Int J Oncol. 2013 Feb;42(2):444-52. (PMID: 23229133)
Pathophysiology. 2000 Sep;7(3):153-163. (PMID: 10996508)
Recent Pat Anticancer Drug Discov. 2012 Jan;7(1):64-73. (PMID: 21854362)
Annu Rev Biomed Eng. 2007;9:415-47. (PMID: 17651012)
Evid Based Complement Alternat Med. 2014;2014:280120. (PMID: 24963320)
Mar Drugs. 2019 May 13;17(5):. (PMID: 31086026)
Toxicol Pathol. 2007 Jun;35(4):495-516. (PMID: 17562483)
Food Chem Toxicol. 2013 Mar;53:62-8. (PMID: 23220614)
World J Clin Oncol. 2011 Jan 10;2(1):8-27. (PMID: 21603311)
Biomolecules. 2019 Nov 13;9(11):. (PMID: 31766246)
Ultrasound Med Biol. 2009 Apr;35(4):672-9. (PMID: 19110365)
CA Cancer J Clin. 2019 Jan;69(1):7-34. (PMID: 30620402)
Ultrasound Med Biol. 2007 Aug;33(8):1285-95. (PMID: 17490808)
Cancer Immunol Immunother. 2017 Feb;66(2):247-258. (PMID: 27585790)
Free Radic Biol Med. 1989;6(6):593-7. (PMID: 2546864)
J Athl Train. 2002 Jul;37(3):293-9. (PMID: 16558674)
Best Pract Res Clin Endocrinol Metab. 2012 Dec;26(6):711-23. (PMID: 23168274)
Mol Med Rep. 2020 Mar;21(3):989-998. (PMID: 32016465)
Sci Rep. 2014 Nov 24;4:7160. (PMID: 25418113)
Biomed Eng Online. 2019 Jun 26;18(1):77. (PMID: 31242902)
Oncotarget. 2016 Mar 29;7(13):15986-6002. (PMID: 26910119)
J Ultrasound Med. 2010 Jun;29(6):963-74. (PMID: 20498470)
Mol Med Rep. 2014 Dec;10(6):3282-8. (PMID: 25324182)
Mol Med Rep. 2019 Nov;20(5):4576-4586. (PMID: 31702038)
Oman Med J. 2016 Mar;31(2):89-97. (PMID: 27168918)
Int J Mol Sci. 2019 May 29;20(11):. (PMID: 31146370)
Free Radic Res. 2010 May;44(5):479-96. (PMID: 20370557)
PLoS One. 2020 Jan 29;15(1):e0222126. (PMID: 31995555)
J Ther Ultrasound. 2017 May 17;5:11. (PMID: 28523127)
PLoS One. 2010 Sep 27;5(9):e13026. (PMID: 20885957)
Sci Rep. 2017 Apr 25;7(1):1325. (PMID: 28465513)
Cancer Genomics Proteomics. 2021 May-Jun;18(3 Suppl):471-486. (PMID: 33994369)
Onco Targets Ther. 2018 Aug 10;11:4723-4732. (PMID: 30127620)
Int J Mol Sci. 2014 Sep 29;15(10):17380-95. (PMID: 25268613)
Biochim Biophys Acta. 2016 Dec;1863(12):2977-2992. (PMID: 27646922)
Aging (Albany NY). 2020 Jan 30;12(2):1760-1777. (PMID: 32003758)
Int J Oncol. 2007 Sep;31(3):601-6. (PMID: 17671687)
Curr Pharm Biotechnol. 2013;14(8):743-52. (PMID: 24372231)
Rheumatology (Oxford). 2002 Mar;41(3):338-42. (PMID: 11934973)
BMJ Open. 2018 Apr 9;8(4):e017249. (PMID: 29632079)
J Clin Oncol. 2013 Apr 20;31(12):1592-605. (PMID: 23509311)
Cell Death Differ. 2006 Sep;13(9):1423-33. (PMID: 16676004)
PLoS One. 2018 Jan 16;13(1):e0191078. (PMID: 29338036)
Ann N Y Acad Sci. 2013 Jul;1291:86-95. (PMID: 23659608)
PLoS One. 2018 Aug 6;13(8):e0201920. (PMID: 30080905)
AJR Am J Roentgenol. 2008 Jan;190(1):191-9. (PMID: 18094311)
Bioorg Chem. 2019 Jul;88:102925. (PMID: 31003078)
Eur J Pharmacol. 2014 Oct 5;740:364-78. (PMID: 25058905)
J Agric Food Chem. 2016 Jul 13;64(27):5484-9. (PMID: 27337169)
PLoS One. 2019 May 31;14(5):e0217676. (PMID: 31150487)

Keywords: combination treatment; hyperthermia; pancreatic cancer; propolis; synergistic effect

9009-62-5 (Propolis)
0 (Reactive Oxygen Species)

Date Created: 20230728 Date Completed: 20230822 Latest Revision: 20230829

20230830

PMC10457055

10.18632/aging.204916

37506229